SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

Area of Science:

• Oncology
• Cancer Biology
• Molecular Biology

Background:

• SMARCA4 (BRG1), a crucial SWI/SNF chromatin remodeler, is frequently inactivated in various cancers.
• Loss of SMARCA4 has been linked to cyclin D1 deficiency and sensitivity to CDK4/6 inhibitors in ovarian cancer.
• Non-small cell lung cancer (NSCLC) represents a significant patient population where SMARCA4 alterations are observed.

Purpose of the Study:

• To investigate the conserved vulnerability of SMARCA4-deficient NSCLC to CDK4/6 inhibition.
• To explore the role of SMARCA2 in regulating cyclin D1 and drug response in the context of SMARCA4 loss.
• To elucidate the molecular mechanisms underlying SMARCA4/2-mediated regulation of cyclin D1 expression.

Main Methods:

• Analysis of SMARCA4 and SMARCA2 function in NSCLC cell lines and patient-derived models.
• Assessment of cyclin D1 expression levels and CCND1 chromatin accessibility.
• Evaluation of c-Jun transcription factor activity.
• In vitro and in vivo studies to determine sensitivity to CDK4/6 inhibitors.

Main Results:

• SMARCA4 loss in NSCLC leads to reduced cyclin D1 expression and increased sensitivity to CDK4/6 inhibitors.
• SMARCA2 loss also impacts cyclin D1 and drug response when SMARCA4 is absent.
• Mechanistically, SMARCA4/2 loss restricts CCND1 chromatin accessibility and suppresses c-Jun.
• Synthetic lethality between SMARCA4 loss and CDK4/6 inhibition was observed in vitro and in vivo.

Conclusions:

• SMARCA4 inactivation creates a druggable vulnerability in a subset of NSCLCs via cyclin D1 deficiency.
• FDA-approved CDK4/6 inhibitors represent a potential therapeutic strategy for SMARCA4-deficient NSCLC.
• Understanding the interplay between SWI/SNF subunits and cell cycle regulation offers new avenues for cancer treatment.